Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Schizophrenia01:17

Schizophrenia

817
Schizophrenia, a term introduced by Swiss psychiatrist Eugen Bleuler in 1911, describes a severe psychological disorder marked by profound disruptions in attention, thought processes, language, emotion, and interpersonal relationships. The core feature of schizophrenia is psychosis — a state characterized by a fundamental detachment from reality. This disconnection manifests through distorted logic, impaired perception, and atypical behavior, severely affecting the lives of those...
817
Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

531
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
531
Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

491
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
491
Forces Acting on Chromosomes02:11

Forces Acting on Chromosomes

3.9K
During mitosis, chromosome movements occur through the interplay of multiple piconewton level forces. In prometaphase, these forces help in chromosome assembly or congression at the equatorial plane, eventually leading to their alignment at the metaphase plate. The forces acting on the chromosomes are space and time-dependent; therefore, they vary with the position of the chromosomes as the cell progresses through mitosis. 
Microtubules and motor proteins exert two types of forces on...
3.9K
Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

488
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
488
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

829
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
829

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk for Autism Across Generations.

Biological psychiatry·2026
Same author

Maternal rheumatoid arthritis and the risk of offspring autism spectrum disorder: two national birth cohorts and a meta-analysis.

Molecular autism·2025
Same author

Telemedicine in Mental Health Care: Therapists' Perspectives on Remote Appointments.

American journal of psychotherapy·2025
Same author

Sex differences in dementia risk: considering underlying medical conditions.

Alzheimer's research & therapy·2025
Same author

The Risk of Very Late-Onset Schizophrenia Following Diabetes Type 2 Onset: A Nationwide Population-Based Study of Midlife and Old-Age.

Schizophrenia bulletin·2025
Same author

The Risk of Dementia Following Hearing Disorder Onset: A National Cohort Study.

Journal of the American Medical Directors Association·2025

Related Experiment Video

Updated: Jan 21, 2026

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
05:51

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

Published on: June 15, 2011

26.4K

[LONG-ACTING INJECTABLE ANTIPSYCHOTICS IN SCHIZOPHRENIA].

Alexander Teitelbaum, Arad Kodesh

    Harefuah
    |July 25, 2019
    PubMed
    Summary

    Long-acting injectable antipsychotics (LAI AP) may be underused in schizophrenia treatment. Pragmatic trials, like the EULAST study, are exploring their benefits in early-phase patients to improve outcomes.

    Area of Science:

    • Psychiatry
    • Pharmacology
    • Clinical Trials

    Background:

    • Long-acting injectable antipsychotics (LAI AP) aim to improve schizophrenia treatment adherence and reduce relapses.
    • Traditional randomized controlled trials (RCTs) often show no LAI AP benefit over oral antipsychotics, unlike observational studies.
    • LAI AP are currently underused and often reserved for severe, late-stage schizophrenia cases.

    Purpose of the Study:

    • To investigate the potential benefits of LAI AP in early-phase schizophrenia patients.
    • To address the underutilization of LAI AP in schizophrenia treatment.
    • To compare the efficacy of LAI AP versus oral antipsychotics in a real-world setting.

    Main Methods:

    • The EULAST study is a pragmatic, randomized, open-label, cohort study.

    More Related Videos

    Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
    07:35

    Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

    Published on: February 4, 2014

    11.9K
    Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization
    12:00

    Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization

    Published on: November 19, 2014

    13.3K

    Related Experiment Videos

    Last Updated: Jan 21, 2026

    A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
    05:51

    A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

    Published on: June 15, 2011

    26.4K
    Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
    07:35

    Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

    Published on: February 4, 2014

    11.9K
    Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization
    12:00

    Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization

    Published on: November 19, 2014

    13.3K
  • It includes a naturalistic follow-up of early-phase schizophrenia patients.
  • This design combines features of RCTs and observational studies.

    • Main Results:

    • Observational studies suggest LAI AP benefits, while RCTs often do not.
    • Pragmatic study designs are more likely to demonstrate LAI AP advantages.
    • Early intervention with LAI AP may offer the greatest benefits for schizophrenia patients.

    Conclusions:

    • LAI AP may be significantly underused in schizophrenia treatment.
    • Early-phase schizophrenia patients might benefit most from LAI AP.
    • The EULAST study aims to clarify the advantages of LAI AP over oral antipsychotics, potentially optimizing patient outcomes.